New study on BNT122: Will Biontech's cancer drug soon boost the share price?

This article is an acquisition from Capital, Capital's premium digital offering.

New study on BNT122: Will Biontech's cancer drug soon boost the share price?

This article is an acquisition from Capital, Capital's premium digital offering. For you as a stern PLUS subscriber, it is available exclusively here for ten days. It will then be available again exclusively for Capital subscribers at www.capital.de/plus. Like stern, the business magazine Capital belongs to RTL Deutschland.

Biontech, known for developing the first vaccine against Corona approved in the EU, is researching the next miracle cure: The company recently published the results of a study on pancreatic cancer. A personalized drug based on mRNA technology was used: BNT122. Biontech tested the drug on patients suffering from pancreatic cancer who had already had an operation. The study results show that BNT122 caused an immune reaction in half of the patients - eight out of 16 participants. In particular, an increase in active T cells was noticeable. Patients who responded positively to the drug experienced a longer period of time without cancer recurrence.

Access to all STERN PLUS content and articles from the print magazine

ad-free

Already registered?

NEXT NEWS